Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) has provided an update.
On October 9, 2025, Palisade Bio announced the cancellation of its special meeting of stockholders, originally scheduled for October 10, 2025, due to a lack of quorum. The company also withdrew the proposals set forth in its definitive proxy statement filed on August 18, 2025, indicating a potential impact on its governance and decision-making processes.
The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
Average Trading Volume: 7,172,847
Technical Sentiment Signal: Sell
Current Market Cap: $205.6M
For detailed information about PALI stock, go to TipRanks’ Stock Analysis page.